Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What CAGR And Valuation Are Anticipated For The Onychomycosis Market?

The size of the onychomycosis market has been on a consistent growth trend in the past few years. It is projected to increase from $3.63 billion in 2024 to $3.81 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. The growth during the historic period is influenced by factors such as restricted treatment alternatives, an older demographic, a rise in diabetes cases, the growth of the pharmaceutical sector, and increased consciousness about fungal infections.

The market size for onychomycosis is anticipated to experience significant expansion in the coming years, surging to $4.78 billion by 2029, with a compound annual growth rate (CAGR) of 5.8%. The projected growth over the forecast period can be credited to the increased utilization of combination drug therapies, escalating healthcare spending, proliferation of educational campaigns about onychomycosis, advancement in telemedicine services, and progress in the formulation of topical drugs. Noteworthy trends within the forecast timeframe comprise the incorporation of digital technology into the diagnosis and treatment of onychomycosis, augmentation of over-the-counter (OTC) antifungal products, emergence of patient-oriented treatment schemes, focus on personalized medicine in managing onychomycosis, and the cooperative research and development efforts among pharmaceutical companies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12197&type=smp

What Core Drivers Are Expected To Influence The Onychomycosis Market?

The growth in the number of diabetics is anticipated to fuel the expansion of the onychomycosis market. Diabetes is a long-term illness characterized by inadequate insulin synthesis by the pancreas or the body’s inefficient utilization of insulin. People with diabetes are often faced with onychomycosis, a prevalent foot complication that can be managed by controlling and handling onychomycosis-associated problems. As a result, the increasing prevalence of diabetes enhances the demand in the onychomycosis market. For example, in June 2024, the UK-based government department, the National Health Service, reported that the NHS discovered over 549,000 extra people throughout England in 2023 who were at risk of developing type 2 diabetes. This brought the total number of pre-diabetic, or non-diabetic hyperglycemia, patients registered with a GP up to 3,615,330. This constitutes a significant increase when compared to the 3,065,825 reported in 2022, marking an uptick of nearly 20%. Hence, the increasing cases of diabetes are driving the growth of the onychomycosis market.

What Are The Main Segment Classifications In The Onychomycosis Market?

The onychomycosismarket covered in this report is segmented –

1) By Type: Distal Subungual Onychomycosis (DSO); White Superficial Onychomycosis (WSO); Proximal Subungual Onychomycosis (PSO); Candida Onychomycosis; Other Types

2) By Treatment: Drug Treatment; Topical Therapy; Other Treatments

3) By Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Distal Subungual Onychomycosis (DSO): Dermatophyte Infections; Mixed Infections

2) By White Superficial Onychomycosis (WSO): Trichophyton Mentagrophytes Infections; Other Non-Dermatophyte Infections

3) By Proximal Subungual Onychomycosis (PSO): Associated with Nail Psoriasis; Fungal Infections In Immunocompromised Patients

4) By Candida Onychomycosis: Candidal Nail Infections; Mixed Fungal-Candida Infections

5) By Other Types: Total Nail Dystrophy; Secondary Onychomycosis

How Are Industry Trends Steering The Expansion Of The Onychomycosis Market?

The rise in product innovation is a significant trend being witnessed in the onychomycosis market. Major players in this market are innovating their offerings to maintain their market standing. This was evident when in January 2024, Vanda Pharmaceuticals Inc., an American biopharmaceutical firm, announced that their VTR-297 had received the approval of the Food and Drug Administration (FDA) for treating onychomycosis. VTR-297 is a small molecule histone deacetylase (HDAC) inhibitor that shows antifungal activity, specifically towards dermatophytes and other fungi, which are common agents causing onychomycosis. The main feature of this drug is its ability to be topically applied, ensuring direct application to the affected nails. This targeted mode of delivery greatly reduces systemic exposure and the probability of side effects that are usually linked with oral antifungal treatments.

Which Companies Are Contributing Significantly To The Onychomycosis Market Growth?

Major companies operating in the onychomycosis market include Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sandoz International GmbH, Bausch Health Companies Inc., Perrigo Company plc, Galderma Laboratories LP, Aurobindo Pharma Limited, Cipla Inc., Dr.Reddy’s Laboratories Ltd., Apotex Inc, Lupin Limited, Amneal Pharmaceuticals Inc., Alembic Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Mayne Pharma Group Limited, Wockhardt Ltd., Jubilant Cadista Pharmaceuticals Inc., Moberg Pharma AB, Medimetriks Pharmaceuticals Inc., Blueberry Therapeutics Ltd., Hallux Inc., NovaBiotics Ltd., Zydus Cadila Healthcare Limited.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Which Region Holds The Greatest Opportunity For Onychomycosis Market Expansion?

North America was the largest region in the onychomycosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onychomycosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12197&type=smp

Browse Through More Reports Similar to the Global Onychomycosis Market 2025, By The Business Research Company

Video Game Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/video-game-software-global-market-report

Video Conferencing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/video-conferencing-global-market-report

Video Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/video-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model